Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management

被引:9
|
作者
Kelly, Scott P. [1 ]
Van den Eeden, Stephen K. [3 ]
Hoffman, Richard M. [4 ]
Aaronson, David S. [3 ]
Lobo, Tania [1 ]
Luta, George [1 ]
Leimpter, Amethyst D. [2 ]
Shan, Jun [2 ]
Potosky, Arnold L. [1 ]
Taylor, Kathryn L. [1 ]
机构
[1] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[3] Kaiser Oakland Med Ctr Northern Calif, Dept Urol, Oakland, CA USA
[4] Univ Iowa, Dept Med, Carver Coll Med, Iowa City, IA 52242 USA
来源
JOURNAL OF UROLOGY | 2016年 / 196卷 / 03期
关键词
prostatic neoplasms; disease progression; watchful waiting; African Americans; early detection of cancer; RADICAL PROSTATECTOMY; FOLLOW-UP; SURVEILLANCE; ANTIGEN; INTERVENTION; PROGRESSION; OUTCOMES; DISPARITIES; TRIGGERS;
D O I
10.1016/j.juro.2016.04.045
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We determined the clinical and sociodemographic predictors of beginning active treatment in an ethnically diverse population of men with low risk prostate cancer initially on observational treatment. Materials and Methods: We retrospectively studied men diagnosed with low risk prostate cancer between 2004 and 2012 at Kaiser Permanente Northern California who did not receive any treatment within the first year of diagnosis and had at least 2 years of followup. We used Cox proportional hazards regression models to determine factors associated with time from diagnosis to active treatment. Results: We identified 2,228 eligible men who were initially on observation, of whom 27% began active treatment during followup at a median of 2.9 years. NonHispanic black men were marginally more likely to begin active treatment than nonHispanic white men independent of baseline and followup clinical measures (HR 1.3, 95% CI 1.0-1.7). Among men who remained on observation nonHispanic black men were rebiopsied within 24 months of diagnosis at a slightly lower rate than nonHispanic white men (HR 0.70, 95% CI 0.6-1.0). Gleason grade progression (HR 3.3, 95% CI 2.7-4.1) and PSA doubling time less than 48 months (HR 2.9, 95% CI 2.3-3.7) were associated with initiation of active treatment independent of race. Conclusions: Sociodemographic factors such as ethnicity and education may independently influence the patient decision to pursue active treatment and serial biopsies during active surveillance. These factors are important for further studies of prostate cancer treatment decision making.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 50 条
  • [31] Low risk is low risk, regardless of race or ethnicity: Outcomes of prostate cancer active surveillance and factors associated with reclassification in a racially diverse cohort
    Labagnara, Kevin
    Zhu, Denzel
    Loloi, Justin
    Shreck, Evan
    Abeshouse, Marnie
    Watts, Kara L.
    Sankin, Alex
    Aboumohamed, Ahmed A.
    Kovac, Evan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (04) : 204e7 - 204e15
  • [32] Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate Cancer
    Womble, Paul R.
    Montie, James E.
    Ye, Zaojun
    Linsell, Susan M.
    Lane, Brian R.
    Miller, David C.
    EUROPEAN UROLOGY, 2015, 67 (01) : 44 - 50
  • [33] Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer
    Jacobs, Bruce L.
    Zhang, Yun
    Schroeck, Florian R.
    Skolarus, Ted A.
    Wei, John T.
    Montie, James E.
    Gilbert, Scott M.
    Strope, Seth A.
    Dunn, Rodney L.
    Miller, David C.
    Hollenbeck, Brent K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (24): : 2587 - 2595
  • [34] Use of advanced treatment technologies among men at low risk of dying from prostate cancer
    Sammon, Jesse D.
    Quoc-Dien Trinh
    Menon, Mani
    BJU INTERNATIONAL, 2014, 114 (02) : 166 - 167
  • [35] Treatment patterns among Canadian men diagnosed with localized low-risk prostate cancer
    Sandoval, C.
    Tran, K.
    Rahal, R.
    Porter, G.
    Fung, S.
    Louzado, C.
    Liu, J.
    Bryant, H.
    CURRENT ONCOLOGY, 2015, 22 (06) : 427 - 429
  • [36] Factors that influence prostate cancer treatment decisions: A qualitative study among a diverse, population-based sample of men with low-risk prostate cancer in Northern California
    Shariff-Marco, Salma
    Shim, Janet
    Allen, Laura
    Kuo, Mei-Chin
    Lau, Kathie
    Golden, Todd
    Loya, Zinnia
    Guan, Alice
    DeRouen, Mindy C.
    Oh, Debora
    Lichtensztajn, Daphne
    Gomez, Scarlett Lin
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [37] PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
    Gaëtan Devos
    Steven Joniau
    BMC Medicine, 18
  • [38] PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
    Devos, Gaetan
    Joniau, Steven
    BMC MEDICINE, 2020, 18 (01)
  • [39] Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer A Decision Analysis
    Hayes, Julia H.
    Ollendorf, Daniel A.
    Pearson, Steven D.
    Barry, Michael J.
    Kantoff, Philip W.
    Stewart, Susan T.
    Bhatnagar, Vibha
    Sweeney, Christopher J.
    Stahl, James E.
    McMahon, Pamela M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (21): : 2373 - 2380
  • [40] Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment
    Dall'Era, Marc A.
    Cowan, Janet E.
    Simko, Jeffrey
    Shinohara, Katsuto
    Davies, Benjamin
    Konety, Badrinath R.
    Meng, Maxwell V.
    Perez, Nannette
    Greene, Kirsten
    Carroll, Peter R.
    BJU INTERNATIONAL, 2011, 107 (08) : 1232 - 1237